Many analysts believe the Republican base’s frustration with the inability of the party to repeal Obamacare makes a Democrat takeover of Congress in 2018 a real possibility. An examination of Democratic health priorities is therefore in order.
Drug companies have begun experimenting with value-based models, largely in response to public outrage over the cost of prescription drugs and the U.S. government’s efforts to rein in those costs.
Chief innovation officers (CInOs) are poised to become one of the more important executives in the C-suite in pharma just as they are in other industries.
“We have not seen the price escalation that has occurred in clinical trials for human drugs,” says Richard Chin, CEO of KindredBio.
It is widely known that women, as well as elderly and minority populations, have long been underrepresented in clinical trials for drugs and biologics. A new study found a similar pattern when it comes to evaluating medical devices.
Can women leaders be responsible and liked – at the same time? Sophie Kornowski-Bonnet, head of Roche partnering, discusses her approach to overcoming adversity, leading to an interesting discussion on if there are differences beyond gender for male versus female executives.
What’s it take to get to the c-suite of a biopharmaceuticals company? For Sophie Kornowski-Bonnet, it was a willingness to step out of her comfort zone. The current head of Roche partnering and executive committee member, shares her intriguing career path, which began in Paris, France, back in 1986.
Prior to joining Lilly as SVP of clinical and product development, Daniel Skovronsky, M.D., Ph.D. was CEO of Avid Radiopharmaceuticals — a company he founded while still a graduate student. This article is a prequel to the upcoming feature in our November issue that explores how he built a $300 million company.
When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”
For antibiotics, we need more investments in basic science, drug discovery, and clinical development. The big risk now is that the market for new antibiotics is absent as any incentive to invest in new medicines fades when their sole purpose would be to be used only exceptionally.
Accenture’s 2017 Technology Vision for Life Sciences examines how major technology trends are shaping the industry and provides recommendations for life sciences companies on how best to take advantage. Across the five trends we uncovered, the unifying theme was how technology is empowering patients and consumers, while driving business results:
Your leadership is the key to keeping your workforce focused, productive, optimistic, and creative no matter what comes your way. Here are three keys to building resilience in today’s dynamic healthcare universe.
The recent settlement of the patent war involving Amgen’s biosimilar to AbbVie’s Humira (adalimumab) has caused rippling in the pharmaceutical industry. The companies had been battling worldwide since at least as early as August 2016, when AbbVie filed a lawsuit against Amgen in the U.S. District Court for the District of Delaware.
The vast majority of rare diseases have no approved treatments available, despite the fact that research related to these diseases has expanded significantly in the past 20 years. A key reason may be the many unique challenges researchers face when developing drugs to treat rare diseases, including difficulties designing and executing effective and appropriate clinical trials.
In the TV series Fear Factor, contestants had to overcome various challenges that most of us found disgusting and/or frightening in order to win a large cash prize. If they failed, their hopes were gone and the contest ended for them. The same can be true for the pharmaceutical industry in trying to achieve the “prize” of being found compliant when audited.
The FDA has released a Draft Guidance titled Use of Electronic Records and Electronic Signatures in Clinical Investigations Under 21 CFR Part 11 – Questions and Answers. Certainly, the development of this draft guidance was driven by the repetitious questions the FDA has received from industry stakeholders as well as the extensive technology advancements.
Based on Amazon's approach to building its business, it is logical to conclude that the online retailer would be an amazing CRO. Amazon’s competitive strategy is to aggressively discount prices to win market share. Plus, its customer obsession and disruptive innovation are second to none. Let’s imagine what an Amazon-run CRO would look like.